-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $190

Benzinga·11/03/2026 15:08:03
RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $187 to $190.